Related Experiment Videos
Pyridoxine-responsive PH1: treatment
1Département médico-chirurgical de Néphrologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Belgium.
Journal of Nephrology
|May 30, 1998
Summary
Pyridoxine therapy for primary hyperoxaluria (PH) shows limited efficacy, with half of patients unresponsive. While some see reduced oxaluria, high doses risk sensory neuropathy.
Area of Science:
- Nephrology
- Metabolic Disorders
- Pharmacology
Background:
- Primary hyperoxaluria (PH) is a rare metabolic disorder.
- Limited data exists on pyridoxine treatment efficacy due to PH rarity.
Purpose of the Study:
- To evaluate the efficacy of pyridoxine therapy in patients with primary hyperoxaluria.
- To assess the impact of pyridoxine on oxaluria levels and kidney function.
Main Methods:
- Analysis of two recent reports involving 18 PH patients treated with pyridoxine.
- Review of reported outcomes on patient response, oxaluria normalization, and kidney function.
Main Results:
- 50% of patients were unresponsive to pyridoxine therapy.
- 20% of patients achieved normalized oxaluria.
- 30% of patients showed a partial reduction in oxaluria.
- Anecdotal cases suggest potential improvement in renal function in some patients.
Conclusions:
- Pyridoxine therapy demonstrates variable and often limited efficacy in primary hyperoxaluria.
- High-dose pyridoxine (0.5-6 g/day) is associated with a risk of severe sensory neuropathy.